Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. Lonial S, et al. Among authors: heffner lt. Clin Cancer Res. 2010 Oct 15;16(20):5079-86. doi: 10.1158/1078-0432.CCR-10-1662. Epub 2010 Aug 25. Clin Cancer Res. 2010. PMID: 20739431 Clinical Trial.
Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connaghan DG, Hillyer CD, Hughes LL, Miller RL, Moore MR, Winton EF, Wingard JR. Holland HK, et al. Among authors: heffner lt. J Clin Oncol. 1996 Apr;14(4):1156-64. doi: 10.1200/JCO.1996.14.4.1156. J Clin Oncol. 1996. PMID: 8648370
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Geller RB, Devine SM, O'Toole K, Persons L, Keller J, Mauer D, Holland HK, Dix SP, Piotti M, Redei I, Connaghan G, Heffner LT, Hillyer CD, Waller EK, Winton EF, Wingard JR. Geller RB, et al. Among authors: heffner lt. Bone Marrow Transplant. 1997 Aug;20(3):219-25. doi: 10.1038/sj.bmt.1700874. Bone Marrow Transplant. 1997. PMID: 9257890 Free PMC article.
Signal transduction and myeloma: new targets, new hope.
Lonial S, Waller EK, Simons JW, Heffner LT Jr. Lonial S, et al. Among authors: heffner lt jr. Cancer Biol Ther. 2003 Jul-Aug;2(4):310-9. doi: 10.4161/cbt.2.4.425. Cancer Biol Ther. 2003. PMID: 14508098 Review.
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC; SUMMIT/CREST Investigators. Lonial S, et al. Among authors: heffner lt. Blood. 2005 Dec 1;106(12):3777-84. doi: 10.1182/blood-2005-03-1173. Epub 2005 Aug 11. Blood. 2005. PMID: 16099887 Free PMC article. Clinical Trial.
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Lonial S, Arellano M, Hutcherson D, Langston A, Flowers C, Heffner LT, Winton E, Jo Lechowicz M, Waller EK. Lonial S, et al. Among authors: heffner lt. Leuk Lymphoma. 2006 Oct;47(10):2155-62. doi: 10.1080/10428190600774923. Leuk Lymphoma. 2006. PMID: 17071490 Clinical Trial.
89 results